CAR-T Cell Generation Using e-Zyvec^® DNA Assembly and FectoVIR^®-LV

Gene-modified cell therapies, such as CAR-T cells, are among the most promising advanced therapy medicinal products (ATMP) in the fight against cancer. These therapies typically use lentiviral vectors to transfer a gene of interest and modify a patient’s cells. The raw materials used during lentiviral vector manufacturing must be carefully selected based on different parameters such as quality, performance, and supplier. 

This application note explores the use of e-Zyvec^® DNA assembly technology to generate a CD19 CAR LV plasmid transgene, which can be used in combination with FectoVIR^® -LV to produce lentiviral particles. The study examines the generation of ex vivo CAR-T cells and their capacity to kill antigen-positive target cells.